logo

For the Inventor, By the Inventor

Davis, CA, United States of America

Jeffrey R Shuster

This inventor holds 23 USPTO granted patents, primarily in Metabolomics Research. Top assignees: Novo Nordisk Biotech, Inc., Paradigm Genetics, Inc., Novo Nordisk A/s. Active years: 1997-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey R Shuster. Retrieved from https://idiyas.com/inventor/jeffrey-r-shuster

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23

% Patents Active = 60.9

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 122(Granted Patents)


Location History:

  • Davis, CA (US) (1997 - 2007)
  • Chapel Hill, NC (US) (2003 - 2015)

Company Filing History:

goldMedal8 out of 63 
 
Novo Nordisk Biotech, Inc.
 patents
silverMedal5 out of 22 
 
Paradigm Genetics, Inc.
 patents
bronzeMedal4 out of 1,803 
 
Novo Nordisk A/s
 patents
4. 3 out of 38 
 
Novozymes Biotech, Inc
 patents
5. 3 out of 384 
 
Novozymes, Inc.
 patents
6. 2 out of 6 
 
Icoria, Inc.
 patents
7. 2 out of 53 
 
Metabolon, Inc.
 patents
8. 1 out of 50 
 
Eastern Virginia Medical School
 patents
9. 1 out of 1,426 
 
Novozymes A/s
 patents
10. 1 out of 3,076 
 
The General Hospital Corporation
 patents
where one patent can have more than one assignee

Years Active: 1997-2015

Loading Chart...
Areas of Expertise:
Metabolomics
Biomarkers
Gene Expression
Fungal Mutants
Antibiotic Inhibitors
Metalloprotease
Non-toxic Systems
Histology
23 patents (USPTO):Explore Patents
1. 8980548 - Methods and reagents for metabolomics and histology in a biological sample and a kit for the same (2015-03-17),
2. 8679457 - Metabolite biomarkers to distinguish Crohn's disease from ulcerative colitis and methods using the same (2014-03-25),
3. 7198938 - Morphological mutants of filamentous fungi (2007-04-03),
4. 7186513 - Methods for monitoring multiple gene expression (2007-03-06),
5. 7163804 - Non-toxic non-toxigenic non-pathogenic fusarium expression system (2007-01-16),
6. 6902887 - Methods for monitoring multiple gene expression (2005-06-07),
7. 6852484 - Methods for the identification of inhibitors of asparagine synthase as antibiotics (2005-02-08),
8. 6806060 - Methods for the identification of inhibitors of threonine synthase as antibiotics (2004-10-19),
9. 6794180 - Morphological mutants of filamentous fungi (2004-09-21),
10. 6740498 - Methods for the identification of inhibitors of histidinol-phosphate as antibiotics (2004-05-25),
11. 6733963 - Methods for the identification of inhibitors of 3-isopropylmalate dehydratase as antibiotics (2004-05-11),
12. 6723529 - Methods for the identification of inhibitors of &agr;-aminoadipate reductase as antibiotics (2004-04-20),
13. 6689578 - Methods for the identification of inhibitors of 5-aminolevulinate synthase as antibiotics (2004-02-10),
14. 6632631 - Methods for the identification of inhibitors of homocitrate synthase as antibiotics (2003-10-14),
15. 6544774 - Morphological mutants of filamentous fungi (2003-04-08),

Title: **Jeffrey R. Shuster: A Pioneer in Metabolomics and Inflammatory Bowel Disease Research**

Introduction

Jeffrey R. Shuster, located in Davis, California, is a notable inventor with an impressive portfolio of 23 patents. His contributions primarily lie in the fields of metabolomics and histology, where he has developed innovative methods and reagents that have significantly advanced the understanding of biochemical analysis in biological samples.

Latest Patents

Among his latest patents, two stand out for their importance in medical diagnostics. The first patent, titled "Methods and reagents for metabolomics and histology in a biological sample and a kit for the same," details a method of extracting and measuring biochemicals from biological samples. This method allows for the immersion of the sample in an organic solvent, enabling the extraction of one or more biochemicals while maintaining the sample’s suitability for histological analysis.

The second patent addresses "Metabolite biomarkers to distinguish Crohn's disease from ulcerative colitis and methods using the same." This innovation identifies biomarkers for inflammatory bowel diseases, facilitating diagnosis, monitoring, and treatment strategies for conditions such as Crohn's disease and ulcerative colitis. The methods associated with these biomarkers not only help in diagnosing these diseases but also provide insights into the efficacy of treatments.

Career Highlights

Jeffrey has held significant roles in industry-leading companies, including Novo Nordisk Biotech, Inc. and Paradigm Genetics, Inc. His experience in these organizations has undoubtedly contributed to his innovative mindset and the development of his patented technologies.

Collaborations

Throughout his career, Jeffrey has collaborated with esteemed colleagues, including John C. Royer and Donna L. Moyer. These partnerships have enriched his research efforts and expanded the impact of his work.

Conclusion

Jeffrey R. Shuster’s work exemplifies the importance of innovation in the life sciences. His patents not only offer groundbreaking methods for analyzing biological samples but also pave the way for improved diagnostic and therapeutic approaches for inflammatory bowel diseases. As he continues to push the boundaries of science, his contributions will undoubtedly have a lasting impact on both research and clinical practices.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…